Results
The project demonstrated that bacterial infections in culture can be detected significantly faster than current clinical practice while fully maintaining existing culture protocols. By combining low-cost commercial gas sensors, a custom gas pre-concentrator, and time-series change-point detection, the project achieved early identification of bacterial growth based on metabolic gas emissions rather than endpoint measurements. This represents a shift from static, delayed diagnostics toward continuous, real-time monitoring of bacterial cultures.
Indicative Impacts
The results of the project introduce a new early-indicator capability that can support clinicians in making timelier and more informed treatment decisions. Faster indication of bacterial growth has the potential to improve clinical outcomes by enabling earlier antibiotic selection, particularly in time-critical scenarios such as intensive care units, post-surgical monitoring, and severe infections.
Clinical microbiology laboratories and hospitals performing routine blood and urine cultures may benefit from reduced diagnostic timelines, improved laboratory throughput, and lower operational costs. From a patient perspective, earlier detection of infection may translate into reduced hospitalisation time, faster recovery, and improved quality of care for patients in both hospital and outpatient settings, including urinary tract infection cases managed at home.
Needs for Further Uptake and Success
To ensure further uptake and successful translation of the results, several steps are required. Protection of the underlying intellectual property at this early stage is essential to enable future commercialisation and engagement with industrial partners. Further research is needed using larger and more diverse bacterial populations to strengthen robustness, assess generalisability, and investigate whether bacterial species differentiation can be achieved using the same real-time data streams.
Additional validation in laboratory and relevant operational environments will be required to progress the technology beyond its current maturity level. Once validated, access to markets and financial support will be necessary to transition from a research prototype to a spin-off or industrial product. Although the proposed methodology does not alter existing clinical culture workflows, engagement with regulatory and standardisation bodies will be important to formally position the technology as an accepted early-indicator tool within clinical diagnostic practice.
Overview of Results
Overall, the project delivered a new diagnostic capability that enables real-time monitoring of bacterial cultures using low-cost sensing hardware and advanced time-series analytics. The results demonstrate that clinically relevant infection thresholds can be detected hours earlier than current standards without modifying established laboratory protocols. This positions the technology as a complementary early-warning tool with strong potential for clinical adoption, further research expansion, and future commercial exploitation.
